Why the ResMed (ASX:RMD) share price just hit an all-time high

A confluence of factors are pushing its share price higher.

| More on:
four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc.(ASX: RMD) share price is breaking new records.

At the time of writing, shares in the healthcare company are trading for $35.28 – up 0.54%. At one point, shares reached an intraday and all-time high of $35.44.

The S&P/ASX 200 Index (ASX: XJO) is also having a record day. Presently, the benchmark index is 0.05% higher but reached a high of 7,417.6 points. While the influence of the general market on the ResMed share price could be having an effect, there may be more to the story.

Let's take a closer look.

Healthcare shares are looking fit

Throughout July, ASX healthcare shares, like ResMed, have been surging. Just in the last month, the ResMed share price has jumped 8.1%, Sonic Healthcare Limited (ASX: SHL) improved 8.2% and CSL Limited (ASX: CSL) shares are up 1.5%.

With COVID back in the spotlight, as the delta variant causes a sharp increase in cases across the world, healthcare shares – including ResMed – may be the few to benefit from this strain of the virus.

Experts too have had nothing but positive words to say about the ResMed share price in recent days.

Analysts at Macquarie Group, for example, say ResMed is a growth share for investors to buy right now. Randal Jenneke, head of Australian equities at T Rowe Price Group, says ResMed is a "quality" share for investors.

Jenneke previously said

Over more than two decades of data for the Australian market, high quality had outperformed low quality by 6.7% per annum.

… [quality shares like ResMed are] poised to outperform over the coming year.

As the ResMed share price has just hit a 52-week high, this advice is being borne out – at least for the time being.

Another factor potentially helping ResMed shares – the falling Aussie dollar.

Experts are tipping it to fall below 70 cents against the greenback. For ASX listed companies that predominately do business in the US, this could be a windfall.

ResMed is one of those companies that predominantly trade in the US. In fact, it is a dual listed company with shares on the New York Stock Exchange.

ResMed share price snapshot

Over the past 12 months, the ResMed share price has increased 23.1%. Year-to-date it is up an even greater 28.3%.

ResMed has a market capitalisation of around $51 billion.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why this beaten down ASX 200 healthcare stock could rebound 66%

Bell Potter sees potential for this healthcare stock to deliver big returns from current levels.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Ahead of its earnings results, Macquarie reckons this healthcare company is severely undervalued

A surprise on the upside is a definite possibility.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Healthcare Shares

3 reasons to buy CSL shares today

A leading investment expert forecasts a stronger year ahead for CSL shares. Let’s see why.

Read more »

A man pulls a shocked expression with mouth wide open as he holds up his laptop.
Healthcare Shares

ASX 200 healthcare stock sinks 9% on FDA update

Let's see what this stock has announced on Thursday.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

3 reasons to buy this heavyweight ASX healthcare share

This one is for investors seeking quality, global reach, and durable earnings.

Read more »

A corporate man crosses his arms to make an X, indicating no deal.
Healthcare Shares

1 reason I'm never selling CSL shares

It might be tempting to offload this one but I think that would be the wrong move.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Why are shares in this biotech charging higher after a capital raise?

More detail has been made public about clinical trial plans.

Read more »

Doctor checking patient's spine x-ray image.
Share Market News

Are these 2 ASX healthcare shares a buying opportunity after yesterday's crash?

ASX healthcare shares have faced headwinds in recent months, but these two could be undervalued.

Read more »